ClinicalTrials.gg
Status unknownNCT04947748Updated Jul 1, 2021

Short Post-operative Antibacterial Therapy in Complicated Appendicitis: Oral Versus Intravenous

An interventional study of Oral versus intravenous administration of antibacterial treatment in Acute Appendicitis, Acute Appendicitis With Rupture and Acute Appendicitis Without Peritonitis, sponsored by North Estonia Medical Centre. Status unknown at 1 site in Estonia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-01.

Sponsored by North Estonia Medical Centre · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jun 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2020, registered Jun 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Short Post-operative Antibacterial Therapy in Complicated Appendicitis: Oral Versus Intravenous is a prospective randomized controlled trial comparing 24 hour intravenous antibacterial therapy to 24 hour oral antibacterial therapy after surgery in complicated appendicitis.

02

Conditions studied

  • Acute Appendicitis
  • Acute Appendicitis With Rupture
  • Acute Appendicitis Without Peritonitis
  • Acute Appendicitis With Appendix Abscess
  • Appendicitis; Perforation
  • Appendicitis Perforated
  • Appendicitis Acute

Browse trials for

03

In context

Appendicitis

421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.

This study's planned enrollment of 100 is below the median of 116 across 254 interventional studies indexed under Appendicitis.

Browse Appendicitis studies →

Lead sponsor

North Estonia Medical Centre is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients diagnosed with acute appendicitis and are candidates for laparoscopic appendectomy.

Exclusion criteria

Exclusion Criteria:

Patients with compromised immune system (, diabetes), ongoing or completed radio-chemotherapy in past 5 years, prosthetic heart valve, vascular prosthesis, pregnancy.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    24 hour intravenous antibacterial therapy

    S.Augmentin 1,2g x 3 i/v

    Other: Oral versus intravenous administration of antibacterial treatment

  • Experimental
    24 hour oral antibacterial therapy

    T.Augmentin 1g x 3 p/o

    Other: Oral versus intravenous administration of antibacterial treatment

Interventions

  • OtherOral versus intravenous administration of antibacterial treatment

    Mode of administration of antibacterial treatment

06

What researchers measure

Primary outcomes

  1. Infectious complications

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2021, 13 months after the start.

Of 92 non-industry interventional studies with no phase under Appendicitis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 13 months is below that.

Counting every sponsor, half of 94 studies reached it within 19 months; a quarter within 10 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
Jul 1, 2021
StartActual
Nov 1, 2020
Primary completionEst.
Dec 31, 2021
CompletionEst.
Dec 31, 2021
Last update
Jul 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04947748
Lead sponsor
North Estonia Medical Centre
Collaborators
Tartu University Hospital
Responsible party
Sponsor
First posted
Jul 1, 2021
Start date
Nov 1, 2020
Primary completion
Dec 31, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Jul 1, 2021

Study contacts

Edgar Lipping, MD
Contact
edgar.lipping@regionaalhaigla.ee
6171520
Sten Saar, MD, PhD
Contact
sten.saar@regionaalhaigla.ee
6171520
Edgar Lipping, MD
principal investigator · North Estonia Medical Centre

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion